The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin

This publication has 26 references indexed in Scilit:

• Safety, Tolerability, and Pharmacokinetics of ICL670, a New Orally Active Iron‐Chelating Agent in Patients with Transfusion‐Dependent Iron Overload Due to β‐Thalassemia
  The Journal of Clinical Pharmacology, 2003
• Development of Tridentate Iron Chelators: From Desferrithiocin to ICL670
  Current Medicinal Chemistry, 2003
• Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial
  The Lancet, 2003
• Deferiprone protects against doxorubicin-induced myocyte cytotoxicity
  Free Radical Biology & Medicine, 2002
• ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture
  Blood, 2001
• Chelator‐induced iron excretion in iron‐overloaded marmosets
  British Journal of Haematology, 2000
• A Comparison of the Free Radical Properties of Several Anthracycline Anti-Tumour Drugs and Some of Their Analogues
  Free Radical Research Communications, 1988
• Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex
  Biochemistry, 1982
• Speciation studies of adriamycin, quelamycin and their metal complexes
  Inorganica Chimica Acta, 1980
• NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals.
  Proceedings of the National Academy of Sciences, 1979